176 related articles for article (PubMed ID: 33946665)
1. Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy.
Álvarez JC; Cuervo SI; Silva E; Díaz JA; Jiménez LL; Parra DS; Gómez JC; Sánchez R; Cortés JA
Antibiotics (Basel); 2021 Apr; 10(5):. PubMed ID: 33946665
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
[TBL] [Abstract][Full Text] [Related]
3. Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies.
Lodl EF; Alshaer MH; Adams CB; Richards A; Peloquin C; Venugopalan V
J Oncol Pharm Pract; 2023 Nov; ():10781552231213883. PubMed ID: 37981806
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.
Whited L; Grove M; Rose D; Rhodes NJ; Scheetz MH; O'Donnell JN; Neeb J; Thoele K; Jones DR; Lowe C; Moore D; Kiel PJ
Pharmacotherapy; 2016 Sep; 36(9):1003-10. PubMed ID: 27496678
[TBL] [Abstract][Full Text] [Related]
6. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
[TBL] [Abstract][Full Text] [Related]
7. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
Bilal M; Zoller M; Fuhr U; Jaehde U; Ullah S; Liebchen U; Büsker S; Zander J; Babouee Flury B; Taubert M
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0030923. PubMed ID: 37366614
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
[TBL] [Abstract][Full Text] [Related]
9. Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies.
Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
Antimicrob Agents Chemother; 2015 Sep; 59(9):5463-9. PubMed ID: 26124158
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
[TBL] [Abstract][Full Text] [Related]
11. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy.
Carlier M; Taccone FS; Beumier M; Seyler L; Cotton F; Jacobs F; Roberts JA
Int J Antimicrob Agents; 2015 Oct; 46(4):413-9. PubMed ID: 26208469
[TBL] [Abstract][Full Text] [Related]
13. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.
Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155
[TBL] [Abstract][Full Text] [Related]
15. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
16. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.
Chaijamorn W; Charoensareerat T; Srisawat N; Pattharachayakul S; Boonpeng A
J Intensive Care; 2018; 6():61. PubMed ID: 30221005
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Vancomycin among Patients with Chemotherapy-Associated Febrile Neutropenia: Which Would Be the Best Dosing to Obtain Appropriate Exposure?
Parra González D; Pérez Mesa JA; Cuervo Maldonado SI; Díaz Rojas JA; Cortés JA; Silva Gómez E; Saavedra Trujillo CH; Gómez J
Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36358178
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia.
Jaruratanasirikul S; Wongpoowarak W; Jullangkoon M; Samaeng M
J Pharmacol Sci; 2015 Feb; 127(2):164-9. PubMed ID: 25727953
[TBL] [Abstract][Full Text] [Related]
19. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
[TBL] [Abstract][Full Text] [Related]
20. Study of Common Bacterial and Fungal Pathogens in Children with Hematological Malignancies during Febrile Neutropenia: Single Center Egyptian Study.
Hagag AA; Hassan SM; Elgamasy MA; Afifi IK
Infect Disord Drug Targets; 2016; 16(1):54-62. PubMed ID: 26715443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
